HC Wainwright Cuts Earnings Estimates for Dyne Therapeutics

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Analysts at HC Wainwright cut their FY2026 EPS estimates for shares of Dyne Therapeutics in a research report issued on Friday, November 6th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings per share of ($3.83) for the year, down from their previous forecast of ($3.82). HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q4 2026 earnings at ($0.95) EPS, Q1 2027 earnings at ($0.91) EPS, FY2027 earnings at ($3.42) EPS, FY2028 earnings at ($2.15) EPS and FY2029 earnings at ($0.84) EPS.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.15). During the same quarter in the previous year, the company earned ($0.76) EPS.

Several other research firms also recently commented on DYN. Cantor Fitzgerald restated a “buy” rating on shares of Dyne Therapeutics in a report on Wednesday, September 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Thursday, October 15th. Stifel Nicolaus set a $37.00 price target on Dyne Therapeutics in a research report on Wednesday, September 30th. Chardan Capital restated a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, September 30th. Finally, Raymond James Financial restated a “strong-buy” rating and set a $37.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.29.

Dyne Therapeutics Stock Up 3.0%

Shares of NASDAQ DYN opened at $18.62 on Tuesday. Dyne Therapeutics has a 52-week low of $14.00 and a 52-week high of $27.31. The firm has a market capitalization of $3.48 billion, a price-to-earnings ratio of -5.13 and a beta of 1.22. The stock has a 50 day moving average price of $17.57 and a 200 day moving average price of $19.34. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in Dyne Therapeutics during the second quarter valued at about $275,500,000. Jupiter Topco LLC purchased a new stake in shares of Dyne Therapeutics during the second quarter valued at about $266,634,000. Perceptive Advisors LLC lifted its position in shares of Dyne Therapeutics by 34.2% during the first quarter. Perceptive Advisors LLC now owns 4,668,839 shares of the company’s stock valued at $84,646,000 after buying an additional 1,189,895 shares during the last quarter. Orbimed Advisors LLC boosted its holdings in shares of Dyne Therapeutics by 32.5% in the 1st quarter. Orbimed Advisors LLC now owns 2,917,884 shares of the company’s stock valued at $52,901,000 after buying an additional 715,700 shares in the last quarter. Finally, Bank of America Corp DE bought a new stake in shares of Dyne Therapeutics in the 2nd quarter valued at about $49,604,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, insider Douglas Kerr sold 3,745 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $24.35, for a total transaction of $91,190.75. Following the completion of the sale, the insider owned 163,854 shares in the company, valued at $3,989,844.90. This represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Cox sold 5,658 shares of the stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total value of $106,823.04. Following the sale, the chief executive officer directly owned 357,507 shares in the company, valued at $6,749,732.16. This trade represents a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 2,598,706 shares of company stock valued at $65,432,671 in the last ninety days. Company insiders own 9.46% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue.

The company’s programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy.